%0 Journal Article
%T Nanovaccines for Cancer Prevention and Immunotherapy: An Update Review.
%A Fang X
%A Lan H
%A Jin K
%A Gong D
%A Qian J
%A Fang X
%A Lan H
%A Jin K
%A Gong D
%A Qian J
%A Fang X
%A Lan H
%A Jin K
%A Gong D
%A Qian J
%J Cancers (Basel)
%V 14
%N 16
%D Aug 2022 9
%M 36010836
%F 6.575
%R 10.3390/cancers14163842
%X Cancer immunotherapy has received more and more attention from cancer researchers over the past few decades. Various methods such as cell therapy, immune checkpoint blockers, and cancer vaccines alone or in combination therapies have achieved relatively satisfactory results in cancer therapy. Among these immunotherapy-based methods, cancer vaccines alone have not yet had the necessary efficacy in the clinic. Therefore, nanomaterials have increased the efficacy and ef-fectiveness of cancer vaccines by increasing their half-life and durability, promoting tumor mi-croenvironment (TME) reprogramming, and enhancing their anti-tumor immunity with minimal toxicity. In this review, according to the latest studies, the structure and different types of nanovaccines, the mechanisms of these vaccines in cancer treatment, as well as the advantages and disadvantages of these nanovaccines are discussed.